Show Summary Details
Page of



Rakesih Jalali

, Patrick Y. Wen

, and Takamitsu Fujimaki

Page of

PRINTED FROM OXFORD MEDICINE ONLINE ( © Oxford University Press, 2021. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 25 February 2021

Meningiomas are the most common type of primary brain tumour, comprising approximately one-third of all intracranial neoplasms. It is therefore important for all neuro-oncologists to understand the biology and optimal managements of these tumours. The majority of meningiomas are World Health Organization grade I benign tumours, but grade II (atypical) or grade III (anaplastic) tumours are not uncommon. Total surgical removal is the standard of care but may not be feasible if the tumour involves critical structures such as cranial nerves or important blood vessels. Conventional radiation therapy, stereotactic radiosurgery, or particle irradiation is used for residual or recurrent tumours. To date, medical treatments have had a limited role, except for controlling seizures. However, there are ongoing clinical trials with molecularly targeted drugs and immunotherapies based on improved understanding of the molecular pathogenesis of these tumours. In this chapter, the clinical presentation, biology, and therapy for these tumours are discussed.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.